Novo Nordisk said it will discontinue its cell therapy R&D efforts and lay off nearly all of the roughly 250 employees working in the unit as part of a broader reorganization under new CEO Maziar Doustdar. The move ends work on cell therapy programs across Parkinson’s disease, chronic heart failure and Type 1 diabetes. The company said it is seeking partners to continue development of existing assets but will reprioritize resources toward obesity and metabolic programs. The cuts form part of a €1.3 billion cost-savings plan that includes global workforce reductions totaling about 9,000 roles. The decision underscores a recent industry pullback from in-house cell therapy platforms and highlights commercial and manufacturing barriers that have prompted some large pharmas to reallocate R&D budgets.